{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T01:23:19Z","timestamp":1778548999639,"version":"3.51.4"},"reference-count":29,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2023,5,31]]},"DOI":"10.1536\/ihj.22-583","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T22:18:06Z","timestamp":1685485086000},"page":"365-373","source":"Crossref","is-referenced-by-count":5,"title":["Gefitinib Increases the Incidence of QT Prolongation in Patients with Non-Small Cell Lung Cancer"],"prefix":"10.1536","volume":"64","author":[{"given":"Gulinigaer","family":"Maimaitituersun","sequence":"first","affiliation":[{"name":"First Affiliated Hospital of Xinjiang Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burebiguli","family":"Abulimiti","sequence":"additional","affiliation":[{"name":"Fourth People's Hospital of Urumqi"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Menglong","family":"Jin","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Xinjiang Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinxin","family":"Dong","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Xinjiang Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenyan","family":"Fu","sequence":"additional","affiliation":[{"name":"Second Department of Coronary Heart Disease, The First Affiliated Hospital of Xinjiang Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Alanazi A, Yunusa I, Elenizi K, Alzarea AI. Efficacy and safety of tyrosine kinase inhibitors in advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation: a network meta-analysis. Lung Cancer Manag 2021; 10: T43.","DOI":"10.2217\/lmt-2020-0011"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Sun X, Xu S, Yang Z, Zheng P, Zhu W. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: a patent review (2014-present). Expert Opin Ther Pat 2021; 31: 223-38.","DOI":"10.1080\/13543776.2021.1860210"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Skoulidis F, Heymach JV. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer 2019; 19: 495-509.","DOI":"10.1038\/s41568-019-0179-8"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Huang J, Meng L, Yang B, Sun SS, Luo ZG, Chen H. Safety profile of epidermal growth factor receptor tyrosine kinase inhibitors: a disproportionality analysis of FDA Adverse Event Reporting System. Sci Rep 2020; 10: 4803.","DOI":"10.1038\/s41598-020-61571-5"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Ayati A, Moghimi S, Salarinejad S, Safavi M, Pouramiri B, Foroumadi A. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. Bioorg Chem 2020; 99: 103811.","DOI":"10.1016\/j.bioorg.2020.103811"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Igawa S, Kasajima M, Ono T, <i>et al<\/i>. A prospective observational study of osimertinib for chemo-naive elderly patients with EGFR mutation-positive non-small cell lung cancer. Cancer Manag Res 2021; 13: 8695-705.","DOI":"10.2147\/CMAR.S339891"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Grabowska ME, Chun B, Moya R, Saucerman JJ. Computational model of cardiomyocyte apoptosis identifies mechanisms of tyrosine kinase inhibitor-induced cardiotoxicity. J Mol Cell Cardiol 2021; 155: 66-77.","DOI":"10.1016\/j.yjmcc.2021.02.014"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Zaborowska-Szmit M, Krzakowski M, Kowalski DM, Szmit S. Cardiovascular complications of systemic therapy in non-small-cell lung cancer. J Clin Med 2020; 9: 1268.","DOI":"10.3390\/jcm9051268"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Cheng HW, Liu HY, Du Q, <i>et al<\/i>. Efficacy and safety of domestic and imported gefitinib in patients with advanced non-small cell lung cancer. Ann Palliat Med 2021; 10: 10-5.","DOI":"10.21037\/apm-20-2140"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Wu YL, Cheng Y, Zhou XD, <i>et al<\/i>. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol 2017; 18: 1454-66.","DOI":"10.1016\/S1470-2045(17)30608-3"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Lynch DR, Kickler TS, Rade JJ. Recurrent myocardial infarction associated with gefitinib therapy. J Thromb Thrombolysis 2011; 32: 120-4.","DOI":"10.1007\/s11239-010-0539-4"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Alhoshani A, Alanazi FE, Alotaibi MR, <i>et al<\/i>. EGFR inhibitor gefitinib induces cardiotoxicity through the modulation of cardiac PTEN\/Akt\/FoxO3a pathway and reactive metabolites formation: in vivo and in vitro rat studies. Chem Res Toxicol 2020; 33: 1719-28.","DOI":"10.1021\/acs.chemrestox.0c00005"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Omori S, Oyakawa T, Naito T, Takahashi T. Gefitinib-induced cardiomyopathy in epidermal growth receptor-mutated NSCLC. J Thorac Oncol 2018; 13: e207-8.","DOI":"10.1016\/j.jtho.2018.05.020"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Han D, Tan H, Sun C, Li G. Amiodarone-induced life-threatening torsade de pointes in an end-stage lung cancer patient receiving gefitinib. Oxf Med Case Rep 2019; 01: omy122.","DOI":"10.1093\/omcr\/omy122"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Robison LB, Brady WJ, Robison RA, Charlton N. QT interval prolongation and the risk of malignant ventricular dysrhythmia and\/or cardiac arrest: systematic search and narrative review of risk related to the magnitude of QT interval length. Am J Emerg Med 2021; 49: 40-7.","DOI":"10.1016\/j.ajem.2021.05.032"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Chandrasekhar S, Fradley MG. QT interval prolongation associated with cytotoxic and targeted cancer therapeutics. Curr Treat Options Oncol 2019; 20: 55.","DOI":"10.1007\/s11864-019-0657-y"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Indraratna P, Tardo D, Delves M, Szirt R, Ng B. Measurement and management of QT interval prolongation for general physicians. J Gen Intern Med 2020; 35: 865-73.","DOI":"10.1007\/s11606-019-05477-7"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Khatib R, Sabir FRN, Omari C, Pepper C, Tayebjee MH. Managing drug-induced QT prolongation in clinical practice. Postgrad Med J 2021; 97: 452-8.","DOI":"10.1136\/postgradmedj-2020-138661"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Bulletin DT. QT interval and drug therapy. Drug Ther Bull 2016; 54: 33-6.","DOI":"10.1136\/dtb.2016.3.0390"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Porta-S\u00e1nchez A, Gilbert C, Spears D, <i>et al<\/i>. Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: a systematic review. JAHA 2017; 6: e007724.","DOI":"10.1161\/JAHA.117.007724"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Waliany S, Zhu H, Wakelee H, <i>et al<\/i>. Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic NSCLC. J Thorac Oncol 2021; 16: 2029-39.","DOI":"10.1016\/j.jtho.2021.07.030"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kim PY, Irizarry-Caro JA, Ramesh T, Iliescu C, Lopez-Mattei JC. How to diagnose and manage QT prolongation in cancer patients. JACC Cardiooncol 2021; 3: 145-9.","DOI":"10.1016\/j.jaccao.2021.01.002"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Lin TC. Gefitinib modulates stress fibers and tubular-like structure formation and attenuates angiogenesis in an in vivo chicken model of chorioallantoic membrane angiogenesis. Biochem Biophys Res Commun 2020; 3: 526.","DOI":"10.1016\/j.bbrc.2020.03.102"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Chu G, Versteeg HH, Verschoor AJ, <i>et al<\/i>. Atrial fibrillation and cancer-An unexplored field in cardiovascular oncology. Blood Rev 2019; 35: 59-67.","DOI":"10.1016\/j.blre.2019.03.005"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Sueta D, Tabata N, Akasaka T, Yamashita T, Ikemoto T, Hokimoto S. The dawn of a new era in onco-cardiology: the Kumamoto Classification. Int J Cardiol 2016; 220: 837-41.","DOI":"10.1016\/j.ijcard.2016.06.330"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Lu ZJ, Luu Y, Ip J, <i>et al<\/i>. The risk of QTc prolongation in non-diabetic and diabetic patients taking tyrosine kinase inhibitors (TKIs) - A patient safety project at a private oncology practice. J Community Hosp Intern Med Perspect 2021; 11: 799-807.","DOI":"10.1080\/20009666.2021.1978652"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf 2013; 36: 295-316.","DOI":"10.1007\/s40264-013-0047-5"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Jie LJ, Li YD, Zhang HQ, <i>et al<\/i>. Mechanisms of gefitinib-induced QT prolongation. Eur J Pharmacol 2021; 910: 174441.","DOI":"10.1016\/j.ejphar.2021.174441"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol 2015; 33: 4210-8.","DOI":"10.1200\/JCO.2015.62.4718"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/64\/3\/64_22-583\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T04:07:32Z","timestamp":1685765252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/64\/3\/64_22-583\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,31]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.22-583","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,31]]},"article-number":"22-583"}}